News | June 23, 2015

First Patients Treated on Elekta Linear Accelerator with Integrated Brainlab ExacTrac X-Ray

Munich hospital using combined system for precision treatment of wide range of cancers

Brainlab, Exactrac, Elekta, Versa HD, LMU Medical Center, Munich

June 23, 2015 - Brainlab announced first patient treatments in March on a fully integrated radiation oncology solution that combines its ExacTrac patient positioning with the Elekta Versa HD linear accelerator (LINAC). Working in synergy, these technologies determine positioning and treatment accuracy for cancer patients.  

By streamlining treatment workflow, ExacTrac and Versa HD increase patient positioning efficiency and provide highly accurate solutions for frameless stereotactic radiosurgery (SRS) and stereotactic body radiotherapy treatment (SBRT). The accuracy is further enriched with the ability to detect and manage intra-fractional patient motion during treatment delivery.

The integrated ExacTrac/Versa HD solution is currently in routine clinical use at Ludwig-Maximilian University Hospital in Munich. To date, the hospital has treated 12 patients with a range of indications and has plans to expand their ExacTrac/Versa HD program.

"The LMU Medical Center prides itself on offering advanced technology and finding new ways to optimize our existing infrastructure. Combining these innovative cancer treatment technologies – Brainlab ExacTrac and Elekta Versa HD – allows us to maximize the benefits of both systems for our patients, including intra-fractional verification," said Prof. Claus Belka, medical director of radiotherapy and radiation oncology at LMU Medical Center, Grosshadern and Innenstadt clinics and polyclinics. "The integrated solution allows us to perform SRS and SBRT cases with submillimetric accuracy and the seamless workflow has allowed us to provide comfortable and fast treatment for patients."

The combined systems enable treatment of conventional as well as complex cancers that require highly accurate targeting precision, expanding the reach and richness of SRS and SBRT for facilities looking to leverage resources and deliver advanced, sophisticated therapies across several different LINACs.

For more information: www.brainlab.com

Related Content

IBA Releases Razor Nano Ionization Chamber
News | Proton Therapy | September 22, 2017
September 22, 2017 — IBA (Ion Beam Applications S.A.) announced the release of the Razor Nano Chamber, the smallest a
Penn Medicine Treats World's First Patient on Varian's Halcyon System
News | Radiation Therapy | September 22, 2017
September 22, 2017 — Varian Medical Systems announced a patient at Penn Medicine, with head & neck cancer, became
BrainLAB Announces FDA Clearance For Two New Indication-Specific Radiosurgery Software Applications
Technology | Treatment Planning | September 21, 2017
Brainlab announced that it has received U.S. Food and Drug Administration (FDA) clearance for Elements Spine SRS and...
Accuray Showcases CyberKnife and Radixact Systems at ASTRO 2017
News | Radiation Therapy | September 21, 2017
Accuray Inc. announced that data and first-hand experience with its advanced CyberKnife and Radixact Systems will be...
RayCare Oncology Information System Being Shown at ASTRO 2017
News | Radiation Therapy | September 20, 2017
RaySearch will be exhibiting its next-generation oncology information system (OIS) RayCare, among other highlights, at...
ProCure Proton Therapy Center New Jersey Celebrates Five-Year Cancer-Free Milestone for Prostate Cancer Patients
News | Proton Therapy | September 20, 2017
ProCure Proton Therapy Center in Somerset, N.J., recently celebrated the five-year cancer-free milestone for the first...
Varian to Showcase Latest Radiation Therapy Technologies and Software at ASTRO 2017
News | Radiation Therapy | September 19, 2017
Varian Medical Systems announced it will be demonstrating its new Halcyon platform and HyperArc high-definition...
Elekta to Highlight MOSAIQ Oncology Analytics at ASTRO Annual Meeting
News | Radiation Therapy | September 19, 2017
September 19, 2017 — Elekta will highlight its Mosaiq Oncology...
Double Targeting Ligands to Identify and Treat Prostate Cancer

The mice were imaged with small-animal PET/CT using 124I-RPS-027 (7.4 MBq [200 μCi]). Credit: JM Kelly et al., Department of Radiology, Weill Cornell Medicine, New York, NY

News | Prostate Cancer | September 14, 2017
Researchers have demonstrated a new, effective way to precisely identify and localize prostate cancer tumors while...
Overlay Init